Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies

Abstract

Background: There has been a paradigm shift in the treatment of Crohn's disease (CD) involving the rapid introduction of biologics and/or immunomodulators after diagnosis. We wished to assess whether this was applied to patients with newly diagnosed CD in a tertiary inflammatory bowel disease referral centre in Israel. Methods: Newly diagnosed CD patients were stratified into 2 groups: the early group was diagnosed between 2005 and 2007 and the late group was diagnosed between 2010 and 2012. Baseline demographics, medical and surgical treatments, disease course and complications during those 2 periods were analyzed. Results: Each group included 60 patients. Significantly higher rates of immunomodulators and biologics were administered to patients in the late group compared to the early group (81.7 and 36.7% compared to 56.7 and 18.3%, p = 0.004 and p = 0.021, respectively). On the other hand, steroid therapy was less prevalent in the late (36.7%) group compared to that of the early group (56.7%), p = 0.059. Medical and surgical CD outcomes, including exacerbations/hospitalizations and surgeries, were comparable for both groups. Conclusions: There was a change in treatment strategy between 2005-2007 and 2010-2012, as reflected in higher proportions of biologics/immunomodulators for patients with newly diagnosed CD. This was associated with a steroid-sparing effect.

Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan

“…Therefore, our insurance system might be one of the reasons for the higher use of biologic agents. The bowel resection rates in patients with IBD vary among different regions and countries [52, 53]. However, we found that the bowel resection rate in patients with IBD has decreased in some newer cohort studies.…”

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

“…As more clinical trial and real-world data on newer agents emerge, clinicians will be better positioned to make decisions about optimal placement of the various advanced therapies. In this context, “big data” and real-world evidence consortia have become pivotal in changing practice, especially for newer agents [16, 17, 22, 23].…”

Capítulo 10 - Aplicação oftalmológica da nanotecnologia

“…Alguns sistemas nanoestruturados mostraram-se capazes de direcionar os ativos especificamente para a retina, como é o caso de nanopartículas superparamagnéticas produzidas com óxido de ferro. Essas nanopartículas puderam ser direcionadas para células-tronco mesenquimais na retina, usando um ímã orbital, além de manter uma segurança de aplicação local por meio de uma liberação controlada do ativo 99 .…”